PNPLA3 in Alcohol‐Related Liver Disease
Liver International · 2025-01 · 45 (1)
DOI: 10.1111/liv.16211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 16.12.2024. Verfasst von Clélia Galvanin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brusse…. Hauptthemen laut MEDLINE: Membrane Proteins, Lipase, Liver Diseases, Alcoholic, Gene-Environment Interaction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: European Union (GENIAL project), French National Agency for Research (France 2030 DELIVER), German Research Foundation.
Abstract (Originalsprache)
The discovery of PNPLA3 as a genetic risk factor for liver disease has transformed our understanding of the pathogenesis of alcohol‐related liver disease (ALD). The recent reclassification of fatty liver disease as steatotic liver disease (SLD), introducing metabolic dysfunction and alcohol‐related liver disease (MetALD), has highlighted how genetic and environmental factors synergistically drive liver damage. The PNPLA3 rs738409 variant stands as a paradigmatic example of gene–environment interaction, where its effect on liver disease is dramatically amplified by alcohol consumption, obesity and type 2 diabetes. Understanding these interactions has revealed novel pathogenic mechanisms. The robust genetic evidence and a growing understanding of molecular mechanisms have made PNPLA3 an attractive therapeutic target. Several compounds targeting PNPLA3 are now in clinical development. While initial trials have focused on metabolic dysfunction‐associated SLD, the recognition that almost all individuals with excessive alcohol consumption have metabolic comorbidities provides an unprecedented opportunity to evaluate these genetically informed therapies in MetALD. In this review, we examine the role of PNPLA3 in ALD, focusing on gene–environment interactions and therapeutic implications in the context of the new disease classification framework.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Medicine I, Dresden University Hospital, Dresden, Germany.
- Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden (TU Dresden), Dresden, Germany.
- Service d'Hépatologie, AP-HP Avicenne, Bobigny, France.
- Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d'Universités et Etablissements Sorbonne Paris Cité, Paris, France.
ORCID-Profile: Clélia Galvanin, Pierre Nahon
Förderung
- European Union (GENIAL project)
- French National Agency for Research (France 2030 DELIVER)
- German Research Foundation
- European Commission
- Agence Nationale de la Recherche
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Galvanin, C., Buch, S., Nahon, P., & Trépo, E. (2025). PNPLA3 in Alcohol‐Related Liver Disease. Liver International, 45(1). https://doi.org/10.1111/liv.16211
Vancouver
Galvanin C, Buch S, Nahon P, Trépo E. PNPLA3 in Alcohol‐Related Liver Disease. Liver International. 2025;45(1). doi:10.1111/liv.16211
BibTeX
@article{Galvanin2025,
author = {Galvanin, Clélia and Buch, Stephan and Nahon, Pierre and Trépo, Eric},
title = {PNPLA3 in Alcohol‐Related Liver Disease},
journal = {Liver International},
year = {2025},
volume = {45},
number = {1},
doi = {10.1111/liv.16211}
}
EUVIMED